Halozyme Raises 2025 and Multi-Year Financial Guidance, Announces $250M Share Repurchase

Details

reiterated its 2024 financial guidance and raised its 2025 and multi-year financial guidance. The company expects total revenue of $1,150 - $1,225 million for 2025, representing year-over-year growth of 16% to 23%. Additionally, the company announced a new $250 million accelerated share repurchase (ASR) program. A conference call to discuss the financial update and guidance was held on the same day.

Items reported

Exhibits (1)

About Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.